A research team that included scientists from The Scripps Research Institute has identified a new group of powerful antibodies to fight Ebola virus. The antibodies could guide the development of a vaccine or therapeutic against Ebola.
The germinal centers that form in the body’s lymph nodes work as a fitness boot camp in which B cells evolve to produce antibodies of increasingly higher affinity to an invading pathogen. This new finding from Whitehead Institute scientists overturns a previously held notion that only a narrow range of B cells can survive this training and go on to secrete high-affinity antibodies. This revised understanding may aid development of effective vaccines against HIV, influenza, and other viruses that mutate rapidly.
Each fall, doctors stress the importance of getting a flu shot: influenza is the most frequent cause of death from a vaccine-preventable disease in the United States. But on-time delivery of the vaccine can be tenuous, and there can be shortages during times of peak demand, as seen in 2014.Research co-authored by Fuqiang Zhang, professor of operations and manufacturing management at Washington University in St.
How well a flu shot protects you from the virus can depend on your ethnic background and other inherited factors, report Dana-Farber Cancer Institute scientists.
Vaccinations, long recognized as an excellent investment that saves lives and prevents illness, could have significant economic value that far exceeds their original cost, a new study from researchers at the Johns Hopkins Bloomberg School of Public Health has found.
A team of researchers lead evaluated the feasibility and impact of different interventions aimed at increasing the number of Tdap vaccinated caregivers.
A new drug with the potential to aid in vaccine development has been identified by researchers at UT Southwestern Medical Center.
Joint statement urges parents, young adults and physicians to act to increase vaccination rates.
BUFFALO, N.Y. — Roswell Park Cancer Institute (RPCI) has joined with all the top cancer centers across the nation in issuing a statement urging for increased HPV vaccination for the prevention of cancer. Recognizing that insufficient vaccination is a public health threat, these leading institutions have called upon the nation’s physicians, parents and young adults to take advantage of this rare opportunity to prevent many types of cancer.
In response to low national vaccination rates for the human papillomavirus (HPV), Moores Cancer Center at UC San Diego Health has joined 68 National Cancer Institute (NCI)-designated cancer centers in issuing a statement urging for increased HPV vaccination.
In response to low national vaccination rates for the human papillomavirus (HPV), VCU Massey Cancer Center has joined with the other 68 of the nation’s top cancer centers – National Cancer Institute-designated cancer centers – in issuing a statement urging for increased HPV vaccination for the prevention of cancer.
National vaccination rates need to be increased for the human papillomavirus (HPV), which causes several types of cancer, The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai and 69 of the nation’s top cancer centers urged today in a joint statement. These institutions collectively recognize insufficient vaccination as a public health threat and call upon the nations’ physicians, parents and young adults to take advantage of this rare opportunity to prevent many types of cancer.
Leaders of several cancer centers designated by the National Cancer Institute have united to support human papillomavirus vaccination. Among them is Cheryl Willman, MD, Director and CEO of the University of New Mexico Comprehensive Cancer Center. The team of HPV experts who drafted the statement included Cosette Wheeler, PhD, at the UNM Comprehensive Cancer Center.
In response to low national vaccination rates for the human papillomavirus, or HPV, Fred Hutchinson Cancer Research Center has joined with 67 other top U.S. cancer centers in issuing a statement urging for increased vaccination in adolescent girls and boys for the prevention of many types of HPV-related cancers in adulthood.
In use for more than 20 years, the varicella zoster virus vaccine for chickenpox and shingles is considered an essential medicine by the World Health Organization (WHO). However, researchers from the University of Missouri School of Medicine have found, in rare instances, a link between the vaccine and corneal inflammation. It is a finding the researchers say should be discussed by primary care physicians and patients with a history of eye inflammation before getting vaccinated.
According to the World Health Organization, influenza causes serious illness among millions of people each year, resulting in 250,000 to 500,000 deaths. Those most at risk include infants younger than six months, because they cannot be vaccinated against the disease. Now, researchers at the University of Missouri School of Medicine have identified a naturally occurring protein that, when added to the flu vaccine, may offer protection to babies during their first months of life.
Physicians have known for years that patients respond differently to vaccines as they age. There may soon be a new way to predict and enhance the effectiveness of vaccinations, in particular the hepatitis B vaccine.
In the first clinical trial of its type, researchers at University of California, San Diego School of Medicine and the Alzheimer’s Disease Cooperative Study (ADCS), in collaboration with AC Immune, a biotechnology company based in Switzerland, will test the safety and tolerability of an immunotherapy vaccine that targets Alzheimer’s disease-like characteristics in adults with Down syndrome.
The Center for Vaccine Development at the University of Maryland School of Medicine will participate in a partnership with industry to develop a vaccine to prevent a group of deadly bacterial infections that occur commonly among hospital patients.
Scientists from The Scripps Research Institute and the Crucell Vaccine Institute have now designed a protein fragment called mini-HA that stimulates the production of antibodies against a variety of influenza viruses. A key part of the work took place at the Stanford Synchrotron Radiation Lightsource (SSRL), a DOE Office of Science User Facility at SLAC National Accelerator Laboratory, where the scientists used a technique called X-ray crystallography to look at the atomic structure of the mini-HA at each stage of its development.
The La Jolla Institute for Allergy and Immunology (LJI) is pleased to announce that an international team led by LJI investigator Alessandro Sette, Ph.D., is one of four recipients of a Human Immune Profiling Consortium (HIPC) grant in 2015. With this prestigious grant, the LJI team will characterize the immune response to dengue virus (DENV) and Mycobacterium tuberculosis (TB), both of which represent major global health challenges.
Mexico has become the first country to approve the use of a dengue fever vaccine that was developed at Saint Louis University in 1997.
A study led a Johns Hopkins University business professor and two colleagues offers a potential remedy by proposing a new kind of contract between flu vaccine manufacturers and the retailers that purchase and dispense the shots to patients.
Within weeks, flu will start spreading. Multiple national recommendations urge all healthcare workers to get the influenza vaccination, to reduce the chances they will pass the virus on to their patients. But a new study finds that more than half of hospitals still don’t require this.
Researchers from The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, in collaboration with the National School of Tropical Medicine at Baylor College of Medicine, have identified a molecule expressed by Trypanosoma cruzi (T. cruzi) that may facilitate the parasite’s evasion of the host’s immune system.
Scientists have discovered new details about how "cloaking" proteins protect the toxin that causes botulism, a fatal disease caused most commonly by consuming improperly canned foods. That knowledge and the cloaking proteins themselves might now be turned against the toxin -- the deadliest known to humankind.
Yale Cancer Center researchers have developed a vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza. The findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.
A program by Stony Brook Children’s Hospital that involves the use of trained community health workers on child immunization reveals that home intervention improves vaccine rates in at-risk children.
Edward Dubovi helped identify H3N2 during last spring's outbreak; says the holidays are a critical time for preventing further spread, strongly recommends vaccinating dogs that spend time at doggie daycare, boarding facilities, dog parks
Approximately 34 percent of children in the United States do not receive all doses of vaccines recommended by the Advisory Committee on Immunization Practices (ACIP) by age 2, according to a new study by researchers at RTI Health Solutions, a business unit of RTI International.
A URI researcher is developing a nicotine vaccine and accompanying drug delivery system that he believes could lead to one of the most effective methods of combating cigarette smoking and other tobacco use.
CSU Professor Ian Orme recently conducted a study that provides new clues to what went wrong with a landmark TB vaccine trial in South Africa.
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality. Researchers at Washington University School of Medicine in St. Louis have identified “broadly neutralizing” antibodies that protect against infection by multiple, distantly related alphaviruses – including Chikungunya virus – that cause fever and debilitating joint pain. The discovery, in mice, lays the groundwork for a single vaccine or antibody-based treatment against many different alphaviruses.
Johns Hopkins Bloomberg School of Public Health researchers say a new candidate vaccine against respiratory syncytial virus (RSV) made with a weakened version of the virus shows great promise at fighting the disease, the leading cause of hospitalization for children under the age of one in the U.S.
A content analysis of nearly 500 anti-vaccination websites found that over two-thirds used what they represented as scientific evidence to support the idea that vaccines are dangerous and nearly one-third contained anecdotes that reinforced the perception.
A new therapeutic vaccine, GTL001, developed by Genticel to clear HPV strains 16 and 18 – the types most likely to cause cancer – is being evaluated for safety in a Phase I clinical trial at the University of Louisville, along with Philadelphia and Columbus, Oh.
One virus creates a long-lived immune reaction in parts of our bodies that serve as our first line of defense against infections, making it a strong candidate for a variety of vaccines.
Analyses of landmark RV144 HIV vaccine study volunteers revealed that those who developed a unique set of vaccine-induced antibodies in combination with a high level of CD4 T-cell responses to the outer portion of the HIV virus, called its envelope gene, correlated with reduced HIV infection.
Researchers at Duke Medicine have discovered that rhesus monkeys can, in fact, transmit Cytomegalovirus (CMV) across the placenta to their unborn offspring. This finding, reported online October 19 in the Proceedings of the National Academy of Sciences, establishes the first primate model that researchers can use to study mother-to-fetus CMV infections and spur development of potential vaccine approaches.
A joint study by UT Southwestern Medical Center and Parkland Health & Hospital System investigators found that a multicomponent outreach program increased completion of the three-dose human papillomavirus (HPV) vaccination series that reduces the risk of cervical cancer caused by the virus.
Scientists at the Tulane National Primate Research Center are leading efforts to find a new vaccine for tuberculosis, one of the world’s deadliest diseases.
Get your flu shot in October for best shot at protection and here's why, says Jorge Parada, MD, infectious disease, Loyola University Health System. Parada explains how the flu serum is formulated and why 2014 was a bad year for the flu.
Researchers found that flu immunizations with four times the strength of standard flu shots significantly reduced the risk of being hospitalized during the influenza season. The group that received the high dose vaccine had a 19.7 percent hospital admission rate versus 20.9 percent in admission for those who received the standard dose vaccine. The findings were presented as a late breaking research presentation on Oct. 10 at the Infectious Diseases Society of America meeting in San Diego.
Using a novel synthetic platform for creating vaccines originally developed in the laboratory of David Weiner, PhD, a professor of Pathology and Laboratory Medicine from the Perelman School of Medicine at the University of Pennsylvania, a team led by his colleagues at the Johns Hopkins University School of Medicine, has successfully eradicated precancerous cervical lesions in nearly half of the women who received the investigational vaccine in a clinical trial.
David Kimberlin, M.D., is the vice chair of Pediatrics, co-director of the Division of Pediatric Infectious Diseases at UAB and a physician at Children’s of Alabama. He is the editor of the American Academy of Pediatrics’ Red Book, which establishes which vaccines should be given, when and to whom. He is also the father of three children.
Every year at this time, we hear it's time to get the flu shot. After last year's vaccine missed the mark, how does the Center for Disease Control regain the public's confidence that their predictions will hold up this year? With the facts.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right